Remove Marketing Remove Pharmaceutical Remove Therapy
article thumbnail

Multi-Mechanical Therapies with Topicals For Age Management

Lipgloss and Aftershave

Phyllis Hsieh is the visionary behind Conrex Pharmaceutical Corp. and the creator of SESHA SKIN THERAPY, a professional skincare brand powered by Patented enhancement technology (P.E.T ) technology. The Permeation Enhancement Technology is FDA-approved in pharmaceuticals.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Jashin Wu, MD, founder and CEO of the Dermatology Research and Education Foundation in San Diego, CA, says that more psoriasis patients will see improvements in their condition due to the influx of new agents and biosimilars on the market. Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., And the Skin Disease of the Year Is….

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology. With a prevalence of approximately 22 million patients in the U.S.

article thumbnail

Biosimilar News: Stada, Alvotech Launch the First Ustekinumab Biosimilar Across Europe

The Dermatology Digest

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

article thumbnail

A Glimpse Inside the Lichen Planus Pipeline

The Dermatology Digest

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Similarly, Incyte and AFYX Therapeutics are developing new therapeutics for lichen planus.

article thumbnail

What does Mandelic Acid do in Deodorants – The Beauty Brains solo

The Beauty Brains

So, pharmaceutical companies are spending money researching this. As you can imagine, this would be a huge market if someone found something that actually worked. I can tell you, the solution is not going to come from a Multilevel marketing company. And a product like this would be a drug. I feel your pain.